Related Experiment Videos
Autotransplants in multiple myeloma: pushing the envelope
S Jagannath1, G Tricot, B Barlogie
1Arkansas Cancer Research Center, Little Rock, USA.
Hematology/Oncology Clinics of North America
|April 1, 1997
Summary
High-dose therapy with autotransplants significantly improves remission rates, duration, and survival in multiple myeloma patients. This treatment is recommended for newly diagnosed patients under 70, even those with renal failure.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Multiple myeloma is a hematologic malignancy with evolving treatment strategies.
- Autotransplantation has emerged as a critical component in managing multiple myeloma.
Purpose of the Study:
- To review the efficacy of autotransplants in multiple myeloma.
- To discuss the feasibility and prognostic factors associated with autotransplantation.
Main Methods:
- Review of major clinical studies on autotransplantation in multiple myeloma.
- Analysis of outcomes including remission rates, duration, and survival.
Main Results:
- High-dose therapy with autotransplants consistently leads to higher remission rates.
- Autotransplants improve remission duration and overall survival in multiple myeloma patients.
- Feasibility in renal failure patients and stem cell selection utility are discussed.
Conclusions:
- Autotransplantation is a key strategy for improving outcomes in multiple myeloma.
- Newly diagnosed multiple myeloma patients under 70 should consider autotransplantation as part of their treatment.
- Further research should explore prognostic factors and optimize stem cell selection.